spartalizumab + LAG525 + NIR178

Spartalizumab + LAG525 + NIR178 is an investigational combination therapy evaluated for advanced solid tumors, specifically advanced triple negative breast cancer. - **Spartalizumab** (PDR001) is a humanized monoclonal antibody that targets the PD-1 (programmed cell death protein 1) receptor, blocking its interaction with PD-L1/PD-L2 and enhancing anti-tumor immune activity. - **LAG525** is a monoclonal antibody targeting LAG-3 (lymphocyte activation gene-3), another immune checkpoint that suppresses T-cell function; its inhibition is designed to further promote immune activation against tumor cells. - **NIR178** (also known as NIR178 or fostamatinib) is an oral small-molecule inhibitor of the adenosine A2A receptor, blocking adenosine-mediated immunosuppression in the tumor microenvironment to further promote immune responses. The combination seeks to augment anti-tumor immune activity by simultaneously targeting multiple immunosuppressive pathways. This regimen has been studied primarily by Novartis in phase 1 clinical trials in metastatic triple negative breast cancer, with the goal of characterizing safety, tolerability, and dose-limiting toxicities[2]. The triple combination is administered intravenously (spartalizumab and LAG525) and orally (NIR178)[2]. The development of this specific combination (PDR001 + LAG525 + NIR178) was discontinued before phase 2 due to limited clinical benefit[2].